Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is expected to continue expanding its profitability as its revenue base shifts towards the higher margin hospital and plasma segments due to advancements in new product launches and acquired technologies. While there has been scrutiny on the commercial execution of the Interventional Technologies segment, the company's solid and increasing operating margins, strong brand reputation, and potential for sustained sales growth through new products and potential mergers and acquisitions makes it attractive for investment. In terms of financials, the company has a goal of achieving an "upper 20s adjusted operating margin" by the end of fiscal year 2026 and is expected to maintain its gross margin forecast while increasing its operating spend and trimming its out years operating margin outlook. Furthermore, the company's recent share repurchases and available capital indicate a focus on both shareholder returns and primary capital allocation priorities such as internal investment and debt reduction in the future.

Haemonetics is facing challenges in its Blood Center and hospital businesses, which appear to be underperforming compared to expectations. The decline in revenue for the Blood Center segment and the underperformance of the hospital segment, particularly in the interventional technologies business, is concerning and may indicate saturation in the market or increased competition. Additionally, the company's recent changes in sales strategy and efforts to stabilize the vascular closure business have yet to yield positive results. As such, there is a high likelihood that the stock will continue to struggle without a significant improvement in these key segments.